COVID-19 VACCINATIONS: If, in addition to indemnity for your main employment, you would like cover for delivering COVID-19 Vaccinations please apply for our standalone extension Apply Today

Home  »   ResourcesLatest NewsPolicy   »   PDA issues advisory information about Paxlovid® antiviral treatment for non-hospitalised patients

PDA issues advisory information about Paxlovid® antiviral treatment for non-hospitalised patients

The NHS is offering antibody and antiviral treatments to people with Covid-19 who are at the highest risk of becoming seriously ill if they contract the virus.

Mon 4th April 2022 The PDA

Paxlovid® is one of four anti-viral therapies available for the treatment of the highest risk patients with Covid-19 infection in the community. Pharmacists are playing an integral part in the supply chain. Whether this is as chief pharmacists in hospital trusts dealing with the order and supply of medications and medicines information, trained pharmacist assessors in the Welsh service, or pharmacists dispensing and delivering antivirals in the Scottish service.

Patients will be assessed to see if they meet the criteria for inclusion and will need careful checking to see if Paxlovid® therapy is safe due to the significant number of drug interactions. Assessment and prescribing are provided via dedicated services with dispensing and supply arranged by the central supply service or via participating community pharmacies.

Every pharmacist can support this service by making themselves familiar with the service set up in their area. This is so that they can provide advice and signpost to healthcare colleagues and patients.

Pharmacists working in general practice may also be able to help with identifying newly diagnosed highest risk patients. Whilst most of this group should have already been identified and contacted, no system is entirely foolproof.

The PDA’s advisory note provides information around indemnity and links to information about the prescribing and adminsitration of Paxlovid® since it is being provided under a temporary authorisation, and is subject to numerous drug-drug interactions, and is a recommended first-line treatment.

Download the advisory note here

thumbnail of Advisory note Paxlovid



Not yet a PDA member?

If you have not yet joined the PDA, we encourage you to join today and ask your colleagues to do the same.

Membership is FREE to pharmacy students, trainee pharmacists and for the first three months of being newly qualified.


Read about our key member benefits here.






The Pharmacists' Defence Association is a company limited by guarantee. Registered in England; Company No 4746656.

The Pharmacists' Defence Association is an appointed representative in respect of insurance mediation activities only of
The Pharmacy Insurance Agency Limited which is registered in England and Wales under company number 2591975
and is authorised and regulated by the Financial Conduct Authority (Register No 307063)

The PDA Union is recognised by the Certification Officer as an independent trade union.

Cookie Use

This website uses cookies to help us provide the best user experience. If you continue browsing you are giving your consent to our use of cookies.

General Guidance Resources Surveys PDA Campaigns Regulations Locums Indemnity Arrangements Pre-Regs & Students FAQs Coronavirus (COVID-19)